Demographic, n (%)* | mCSCC (N=78) |
Sex | |
Female | 19 (24.4) |
Male | 59 (75.6) |
Median age | 71.6 (37–91) |
<65 years | 22 (28.2) |
≥65 years | 56 (71.8) |
Race | |
White | 69 (88.5) |
Asian | 6 (7.7) |
Unknown | 2 (2.6) |
Black or African American | 1 (1.3) |
Ethnicity | |
Not Hispanic or Latino | 73 (93.6) |
Hispanic or Latino | 3 (3.8) |
Unknown | 2 (2.6) |
Country/region | |
Australia/New Zealand | 45 (57.7) |
Europe | 19 (24.4) |
South Africa | 8 (10.3) |
Thailand | 6 (7.7) |
PD-L1 status | |
PD-L1-positive (≥1%) | 37 (47.4) |
PD-L1-negative | 18 (23.1) |
Unknown | 23 (29.5) |
ECOG PS | |
0 | 23 (29.5) |
1 | 55 (70.5) |
Primary CSCC site | |
Head/neck | 46 (59.0) |
Extremity | 18 (23.1) |
Trunk | 9 (11.5) |
Other | 5 (6.4) |
Type of metastatic disease | |
Distant | 52 (66.7) |
Nodal | 26 (33.3) |
Prior cancer-related surgery | 47 (60.3) |
Prior cancer-related radiotherapy | 51 (65.4) |
Prior cancer-related systemic therapy | 7 (9.0) |
*Except for median age, which is presented as years (range).
CSCC, cutaneous squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; mCSCC, metastatic CSCC; PD-L1, programmed cell death-ligand 1.